Enlivex Therapeutics Ltd
NASDAQ:ENLV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.841
4.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd
Selling, General & Administrative
Enlivex Therapeutics Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Selling, General & Administrative
-$5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Selling, General & Administrative
-$6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Selling, General & Administrative
-$33.4m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-12%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Selling, General & Administrative
-$110.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Selling, General & Administrative
-$3.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Selling, General & Administrative
-₪10.6m
|
CAGR 3-Years
36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-10%
|
|
Enlivex Therapeutics Ltd
Glance View
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
See Also
What is Enlivex Therapeutics Ltd's Selling, General & Administrative?
Selling, General & Administrative
-5m
USD
Based on the financial report for Jun 30, 2024, Enlivex Therapeutics Ltd's Selling, General & Administrative amounts to -5m USD.
What is Enlivex Therapeutics Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-12%
Over the last year, the Selling, General & Administrative growth was 27%.
You don't have any saved screeners yet
